Electronic Health Record-Based Detection of Risk Factors for Clostridium difficile Infection Relapse

被引:43
作者
Hebert, Courtney [1 ]
Du, Hongyan [2 ]
Peterson, Lance R. [3 ]
Robicsek, Ari [4 ,5 ]
机构
[1] Ohio State Univ, Wexner Med Ctr, Dept Biomed Informat, Columbus, OH 43210 USA
[2] NorthShore Univ HealthSyst, Ctr Clin & Res Informat, Evanston, IL USA
[3] NorthShore Univ HealthSyst, Dept Pathol, Evanston, IL USA
[4] NorthShore Univ HealthSyst, Ctr Clin & Res Informat, Dept Hlth Informat Technol, Dept Med, Evanston, IL USA
[5] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA
关键词
PROTON-PUMP INHIBITORS; VANCOMYCIN; DIARRHEA; ASSOCIATION; RECURRENCE; THERAPY; STRAIN; DRUGS;
D O I
10.1086/669864
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
OBJECTIVE. A major challenge in treating Clostridium difficile infection (CDI) is relapse. Many new therapies are being developed to help prevent this outcome. We sought to establish risk factors for relapse and determine whether fields available in an electronic health record (EHR) could be used to identify high-risk patients for targeted relapse prevention strategies. DESIGN. Retrospective cohort study. SETTING. Large clinical data warehouse at a 4-hospital healthcare organization. PARTICIPANTS. Data were gathered from January 2006 through October 2010. Subjects were all inpatient episodes of a positive C. difficile test where patients were available for 56 days of follow-up. METHODS. Relapse was defined as another positive test between 15 and 56 days after the initial test. Multivariable regression was performed to identify factors independently associated with CDI relapse. RESULTS. Eight hundred twenty-nine episodes met eligibility criteria, and 198 resulted in relapse (23.9%). In the final multivariable analysis, risk of relapse was associated with age (odds ratio [OR], 1.02 per year [95% confidence interval (CI), 1.01-1.03]), fluoroquinolone exposure in the 90 days before diagnosis (OR, 1.58 [95% CI, 1.11-2.26]), intensive care unit stay in the 30 days before diagnosis (OR, 0.47 [95% CI, 0.30-0.75]), cephalosporin (OR, 1.80 [95% CI, 1.19-2.71]), proton pump inhibitor (PPI; OR, 1.55 [95% CI, 1.05-2.29]), and metronidazole exposure after diagnosis (OR, 2.74 [95% CI, 1.64-4.60]). A prediction model tuned to ensure a 50% probability of relapse would flag 14.6% of CDI episodes. CONCLUSIONS. Data from a comprehensive EHR can be used to identify patients at high risk for CDI relapse. Major risk factors include antibiotic and PPI exposure. Infect Control Hosp Epidemiol 2013;34(4):407-414
引用
收藏
页码:407 / 414
页数:8
相关论文
共 33 条
[1]   Clostridium difficile Outbreak Strain BI Is Highly Endemic in Chicago Area Hospitals [J].
Black, Stephanie R. ;
Weaver, Kingsley N. ;
Jones, Roderick C. ;
Ritger, Kathleen A. ;
Petrella, Laurica A. ;
Sambol, Susan P. ;
Vernon, Michael ;
Burton, Stephanie ;
Garcia-Houchins, Sylvia ;
Weber, Stephen G. ;
Lavin, Mary Alice ;
Gerding, Dale ;
Johnson, Stuart ;
Gerber, Susan I. .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2011, 32 (09) :897-902
[2]   Clinical Predictors and Risk Factors for Relapsing Clostridium difficile Infection [J].
Cadena, Jose ;
Thompson, George R., III ;
Patterson, Jan E. ;
Nakashima, Brandy ;
Owens, Aaron ;
Echevarria, Kelly ;
Mortensen, Eric M. .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2010, 339 (04) :350-355
[3]   Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis [J].
Cadle, Richard M. ;
Mansouri, Mohammad D. ;
Logan, Nancy ;
Kudva, Denise R. ;
Musher, Daniel A. .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2007, 64 (22) :2359-2363
[4]   Risk Factors for Recurrence of Clostridium difficile Infection: Effect of Vancomycin-resistant Enterococci Colonization [J].
Choi, Hee Kyoung ;
Kim, Kye Hyung ;
Lee, Sun Hee ;
Lee, Su Jin .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2011, 26 (07) :859-864
[5]   Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) [J].
Cohen, Stuart H. ;
Gerding, Dale N. ;
Johnson, Stuart ;
Kelly, Ciaran P. ;
Loo, Vivian G. ;
McDonald, L. Clifford ;
Pepin, Jacques ;
Wilcox, Mark H. .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2010, 31 (05) :431-455
[6]   Association Between Proton Pump Inhibitor Therapy and Clostridium difficile Infection in a Meta-Analysis [J].
Deshpande, Abhishek ;
Pant, Chaitanya ;
Pasupuleti, Vinay ;
Rolston, David D. K. ;
Jain, Anil ;
Deshpande, Narayan ;
Thota, Priyaleela ;
Sferra, Thomas J. ;
Hernandez, Adrian V. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2012, 10 (03) :225-233
[7]   Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors:: cohort and case-control studies [J].
Dial, S ;
Alrasadi, K ;
Manoukian, C ;
Huang, A ;
Menzies, D .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2004, 171 (01) :33-38
[8]   Meta-analysis to assess risk factors for recurrent Clostridium difficile infection [J].
Garey, K. W. ;
Sethi, S. ;
Yadav, Y. ;
DuPont, H. L. .
JOURNAL OF HOSPITAL INFECTION, 2008, 70 (04) :298-304
[9]   Iatrogenic Gastric Acid Suppression and the Risk of Nosocomial Clostridium difficile Infection [J].
Howell, Michael D. ;
Novack, Victor ;
Grgurich, Philip ;
Soulliard, Diane ;
Novack, Lena ;
Pencina, Michael ;
Talmor, Daniel .
ARCHIVES OF INTERNAL MEDICINE, 2010, 170 (09) :784-790
[10]   Prospective Derivation and Validation of a Clinical Prediction Rule for Recurrent Clostridium difficile Infection [J].
Hu, Mary Y. ;
Katchar, Kianoosh ;
Kyne, Lorraine ;
Maroo, Seema ;
Tummala, Sanjeev ;
Dreisbach, Valley ;
Xu, Hua ;
Leffler, Daniel A. ;
Kelly, Ciaran P. .
GASTROENTEROLOGY, 2009, 136 (04) :1206-1214